Centre for Biomedical Ethics and Law, Katholieke Universiteit Leuven, Kapucijnenvoer 35 Box 7001, 3000 Leuven, Belgium
Health, Ethics and Society, Faculty of Health, Medicine and Life Sciences & GROW, School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
Hum Reprod. 2015 May;30(5):1256-62. doi: 10.1093/humrep/dev056. Epub 2015 Mar 18.
What are the opinions of professionals in the field of genetics, reproductive science and metabolic diseases on the development of mitochondrial replacement technologies to be used in the context of medically assisted reproduction?
Although concerns regarding safety remain, interviewees supported the development of nuclear transfer techniques to help women who are at risk of transferring a mitochondrial DNA disease to their offspring conceive a genetically related child.
Technological developments in the field of nuclear transfer have sparked new interest in the debate on the acceptability of the use of donor oocytes to prevent the transmission of mitochondrial diseases. For example, in the UK, extensive public consultations have been done to investigate whether such techniques would allow the passing of a law that involves making changes to a human oocyte or embryo before transfer to a woman's body. Until now, continental European countries seem to await the outcome of the British debate before themselves considering the arguments for and against this technology.
STUDY DESIGN, SIZE, AND DURATION: We interviewed 12 professionals from Belgium and The Netherlands.
PARTICIPANTS/MATERIALS, SETTING, AND METHODS: We conducted 12 interviews with fertility specialists, scientists, clinical geneticists, a pediatrician specialized in metabolic diseases and a specialist in metabolic diseases. The profiles of the interviewees varied but all had experience with mitochondrial diseases, either in treating patients or in providing counseling to patients or to prospective parents. The interviews were conducted face-to-face and took 30-45 min. The language of the interviews was Dutch. We analyzed the transcript of these interviews using QSR NVIVO 10 software to extract themes and categories.
This study has shown that, although amongst the professionals we interviewed there was support for the development and deployment of nuclear transfer, this support does not necessarily correspond to uniform opinions about the importance of having a genetically own child or the contribution of mitochondrial DNA to essential characteristics of an individual.
LIMITATIONS, REASONS FOR CAUTION: In translating the quotes from Dutch to English some of the linguistic nuances may have been lost. We only interviewed 12 individuals, in two countries, whose view may not be representative of existing values and opinions that may be held by professionals worldwide on this matter. To further explore the issue at hand, a subsequent investigation of the opinions of people affected by mitochondrial diseases and of the general public is necessary.
With this study we have demonstrated there is in principle support for the nuclear transfer technique from Dutch and Belgian professionals. Further research, both scientific and ethical, is needed to define the modalities of its possible introduction in the fertility clinic.
STUDY FUNDING/COMPETING INTERESTS: This research was funded by GROW, School for Oncology and Developmental Biology, The Netherlands. The authors declare no conflict of interest.
N/A.
遗传学家、生殖科学和代谢疾病领域的专业人士对用于辅助生殖的线粒体替换技术的发展有何看法?
尽管仍存在安全方面的担忧,但受访者支持开发核转移技术,以帮助有风险将线粒体疾病遗传给后代的女性怀上具有遗传关系的孩子。
核转移技术的发展引发了人们对使用供体卵以防止线粒体疾病传播的可接受性的争论。例如,在英国,已经进行了广泛的公众咨询,以调查此类技术是否允许通过立法来改变人类卵子或胚胎,然后再将其转移到女性体内。到目前为止,似乎欧洲大陆国家都在等待英国辩论的结果,然后再考虑支持或反对这项技术的论点。
研究设计、规模和持续时间:我们采访了来自比利时和荷兰的 12 名专业人士。
参与者/材料、地点和方法:我们对 12 名生育专家、科学家、临床遗传学家、专门研究代谢疾病的儿科医生和代谢疾病专家进行了采访。受访者的背景各不相同,但都有治疗患者或为患者或准父母提供咨询方面的线粒体疾病经验。采访是面对面进行的,持续 30-45 分钟。采访的语言是荷兰语。我们使用 QSR NVIVO 10 软件分析了这些采访的记录,以提取主题和类别。
这项研究表明,尽管我们采访的专业人员中有人支持核转移技术的开发和应用,但这种支持并不一定对应于对拥有亲生子女的重要性或线粒体 DNA 对个人基本特征的重要性的一致意见。
局限性、谨慎的原因:在将荷兰语的引语翻译成英语时,可能会丢失一些语言上的细微差别。我们只采访了来自两个国家的 12 个人,他们的观点可能不能代表全球专业人士在这个问题上的现有价值观和意见。为了进一步探讨这个问题,有必要对受线粒体疾病影响的人和公众的意见进行后续调查。
通过这项研究,我们已经证明,荷兰和比利时的专业人员原则上支持核转移技术。需要进一步进行科学和伦理研究,以确定其在生育诊所中可能引入的方式。
研究资金/利益冲突:本研究由荷兰肿瘤学和发育生物学研究生院(GROW)资助。作者没有利益冲突。
无。